Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A “novel transcript, antisense to LRIG2” is likely a newly annotated or predicted non-coding RNA that is transcribed from the DNA strand opposite to that of the LRIG2 gene. Such antisense transcripts sometimes regulate the expression of their sense partner (such as LRIG2) through various mechanisms, but there is no specific published evidence for this transcript having any biological or therapeutic significance. The use of the placeholder "novel transcript" implies this entry is not yet characterized functionally or clinically, and the Ensembl ID does not correspond to a mainstream, validated gene or target. LRIG2, by contrast, is a well-characterized protein-coding gene encoding a transmembrane protein with leucine-rich repeats and immunoglobulin-like domains, involved in cell proliferation and associated with some disease states, but this is distinct from the antisense transcript referred to in your query. The provided target ("novel transcript, antisense to LRIG2", ENSG00000303525) is not a recognized or validated therapeutic target and has unclear or possibly incorrect nomenclature and annotation. If you need information about the actual LRIG2 protein or gene, please specify. If you seek information on this predicted antisense RNA, be aware it is uncharacterized, does not have a canonical identity or function, and is not referenced as a target in reputable databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to LRIG2.